The results from its first-in-human study in the US (ClinicalTrials.gov number, NCT03602079) showed preliminary antitumour activity in patients with relapsed or refractory advanced HER2-altered solid cancers, mostly nonbreast cancers (i.e., HER2-positive gastric cancer, HER2-expressing ovarian cancer, HER2-mutated non-small cell lung cancer), with objective responses occurring in 36% of the patients at dose levels of 3.6 mg/kg and 4.8 mg/kg14. Here, ERBB2 is linked to gastric cancer.